- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ASCO Calls on Congress to Fix Flawed Medicare Payment System
One year ago, ASCO was engaged in an all too familiar exercise: working around the clock to prevent scheduled cuts in Medicare physician payments. If implemented, these cuts would have reduced access to care for many older and disabled Americans. Congress responded with another patch, or temporary fix to avert the harmful cuts.
This has been a steady pattern since 2002, as Congress has had to step in numerous times to avert cuts resulting from the Sustainable Growth Rate—a formula that severely underestimates the costs of treating Medicare patients. Unless Congress steps in again, the formula will result in a 27.4 percent cut to reimbursement rates for 2012. President Obama has proposed to freeze payments at 2011 levels for two years to allow for development of a permanent fix.
A significant cut to Medicare payments as a result of the SGR would create barriers to care for cancer patients by forcing many community-based oncology practices—already grappling with previous Medicare cuts and increased administrative burdens—to limit their services or close altogether.
Read the full article at: http://tinyurl.com/7538yg8
Source: ASCO
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Read More
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Read More
